However, PD-L1 are expressed scatteredly among NSCLC tissues and a series of clinical and pre-clinical studies show that the therapeutic efficiency of PD-1/PD-L1 blockade is highly correlated to its PD-L1 expression [8]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.